Stryker Corporation $SYK Stock Sold by Stillwater Wealth Management Group

Stillwater Wealth Management Group lessened its stake in shares of Stryker Corporation (NYSE:SYK) by 84.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,190 shares of the medical technology company’s stock after selling 6,357 shares during the period. Stillwater Wealth Management Group’s holdings in Stryker were worth $328,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bank of America Corp DE acquired a new stake in Stryker in the 2nd quarter worth about $1,404,284,000. Legal & General Group Plc acquired a new position in shares of Stryker during the second quarter valued at approximately $707,212,000. Jupiter Topco LLC purchased a new position in shares of Stryker in the second quarter valued at approximately $681,581,000. Corient Private Wealth LP purchased a new position in shares of Stryker in the second quarter valued at approximately $323,035,000. Finally, Flossbach Von Storch SE purchased a new position in shares of Stryker in the second quarter valued at approximately $464,506,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Stryker

In related news, insider Dylan Crotty sold 441 shares of Stryker stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ronda Stryker sold 50,000 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the transaction, the director directly owned 2,251,375 shares in the company, valued at $765,692,637.50. This trade represents a 2.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is currently owned by insiders.

Stryker Price Performance

NYSE SYK traded down $7.07 during trading hours on Wednesday, hitting $297.33. 1,193,869 shares of the company’s stock traded hands, compared to its average volume of 2,450,214. The company has a market capitalization of $114.05 billion, a PE ratio of 30.77, a PEG ratio of 1.92 and a beta of 0.78. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a 52-week low of $267.00 and a 52-week high of $392.55. The firm’s 50-day moving average is $297.53 and its 200-day moving average is $312.37.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same period last year, the company posted $3.13 EPS. The business’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts forecast that Stryker Corporation will post 14.93 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on SYK. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Stryker in a research note on Wednesday, October 7th. Royal Bank Of Canada reduced their price objective on Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. JPMorgan Chase & Co. decreased their price objective on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. UBS Group started coverage on Stryker in a report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price objective on the stock. Finally, Evercore set a $350.00 target price on shares of Stryker in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus target price of $369.00.

Stryker Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.